Table 1.
Demographic and clinical characteristics according to mitral valve prolapse status
| Mitral valve prolapse (n=41) |
Controls (n=31) |
p Value | |
|---|---|---|---|
| Age, years median (IQR) | 50 (47, 57) | 49 (37, 60) | 0.37 |
| Male, n (%) | 25 (61) | 18 (59) | 0.19 |
| BSA, m2 median (IQR) | 1.9 (1.72, 2.0) | 2.0 (1.8, 2.2) | 0.13 |
| SBP, mm Hg mean (SD) | 142 (26) | 146 (25) | 0.49 |
| DBP, mm Hg mean (SD) | 63 (11) | 62 (11) | 0.55 |
| Heart rate, beats/min median (IQR) | 63 (56,72) | 57 (51,67) | 0.14 |
| eGFR, mL/min/1.73 m2 mean (SD) | 70 (11) | 74 (10) | 0.06 |
| Dyspnoea, n (%) | 10 (24) | 0 (0) | <0.001 |
| NYHA class I, n (%) | 31 (76) | 31 (100) | 0.004 |
| NYHA class II, n (%) | 7 (17) | 0 (0) | 0.02 |
| NYHA class III, n (%) | 3 (7) | 0 (0) | 0.25 |
| NYHA class IV, n (%) | 0 (0) | 0 (0) | N/A |
| Current medication: | |||
| β-Blocker, n (%) | 15 (37) | 0 (0) | <0.001 |
| Calcium channel blocker, n (%) | 2 (5) | 0 (0) | 0.21 |
| ACE inhibitor, n (%) | 15 (37) | 0 (0) | <0.001 |
| ARB, n (%) | 0 (0) | 0 (0) | N/A |
| Diuretics, n (%) | 5 (12) | 0 (0) | 0.04 |
| Diabetes, n (%) | 2 (5) | 0 (0) | 0.21 |
| Current tobacco use, n (%) | 2 (5) | 0 (0) | 0.21 |
Categorical variables are presented as number of patients (%). Continuous variables are presented as median (IQR) or mean (SD).
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BSA, body surface area; eGFR, estimated glomerular filtration rate; N/A, not applicable; NYHA, New York Heart Association functional class; SBP/DBP, systolic/diastolic blood pressure.
P-value <0.05 are shown in bold.